Seattle Genetics Inc. (SGEN)

76.29
NASDAQ : Health Technology
Prev Close 78.36
Day Low/High 75.73 / 78.82
52 Wk Low/High 50.71 / 84.37
Avg Volume 952.70K
Exchange NASDAQ
Shares Outstanding 168.86M
Market Cap 13.23B
EPS -1.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Seattle Genetics Announces Proposed Public Offering Of Common Stock

Seattle Genetics Announces Proposed Public Offering Of Common Stock

Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that it has commenced an underwritten public offering of 6,000,000 shares of its common stock.

Seattle Genetics Has a Rally in Its DNA

Seattle Genetics Has a Rally in Its DNA

Here's how to play this biotech stock.

Big Victory for the Bulls: Cramer's 'Mad Money' Recap (Monday 7/22/19)

Big Victory for the Bulls: Cramer's 'Mad Money' Recap (Monday 7/22/19)

Jim Cramer says that in the heart of earnings season, Wall Street analysts can make important calls that let bulls push stocks higher.

Berkshire Hathaway, Seattle Genetics, Zynerba: 'Mad Money' Lightning Round

Berkshire Hathaway, Seattle Genetics, Zynerba: 'Mad Money' Lightning Round

Jim Cramer takes a look at Berkshire Hathaway, Seattle Genetics, Zynerba Pharmaceuticals, Range Resources, Guardant Health, Danaher and more.

Seattle Genetics Reports Second Quarter 2019 Financial Results

Seattle Genetics Reports Second Quarter 2019 Financial Results

Seattle Genetics, Inc. (Nasdaq:SGEN) today reported financial results for the second quarter and six months ended June 30, 2019.

Astellas And Seattle Genetics Announce Submission Of Biologics License Application To FDA For Enfortumab Vedotin For Patients With Locally Advanced Or Metastatic Urothelial Cancer

Astellas And Seattle Genetics Announce Submission Of Biologics License Application To FDA For Enfortumab Vedotin For Patients With Locally Advanced Or Metastatic Urothelial Cancer

-Submission Based on Pivotal Phase 2 Trial Results Recently Presented at Annual Meeting of American Society of Clinical Oncology-

Seattle Genetics To Host Conference Call And Webcast Discussion Of Second Quarter 2019 Financial Results On July 16, 2019

Seattle Genetics To Host Conference Call And Webcast Discussion Of Second Quarter 2019 Financial Results On July 16, 2019

Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its second quarter 2019 financial results on Tuesday, July 16, 2019 after the close of financial markets.

Natasha A. Hernday Elected To PDL BioPharma's Board Of Directors

Natasha A. Hernday Elected To PDL BioPharma's Board Of Directors

INCLINE VILLAGE, Nev., June 24, 2019 /PRNewswire/ -- PDL BioPharma, Inc.

Seattle Genetics Announces Multiple ADCETRIS® (Brentuximab Vedotin) Presentations At The Congress Of The European Hematology Association (EHA) And The International Conference On Malignant Lymphoma (ICML)

Seattle Genetics Announces Multiple ADCETRIS® (Brentuximab Vedotin) Presentations At The Congress Of The European Hematology Association (EHA) And The International Conference On Malignant Lymphoma (ICML)

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced data from its ADCETRIS ® (brentuximab vedotin) clinical development program at the 24 th Annual Congress of the European Hematology Association (EHA) taking place June 13-16 in Amsterdam; and the...

Seattle Genetics' Antibody-Drug Conjugate Technology Utilized In Genentech's Polivy, Now Approved By FDA

Seattle Genetics' Antibody-Drug Conjugate Technology Utilized In Genentech's Polivy, Now Approved By FDA

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced U.

Seattle Genetics Announces Additional Analyses Of ECHELON-1 And ECHELON-2 Phase 3 Clinical Trials Of ADCETRIS® (Brentuximab Vedotin) At The 2019 ASCO Annual Meeting

Seattle Genetics Announces Additional Analyses Of ECHELON-1 And ECHELON-2 Phase 3 Clinical Trials Of ADCETRIS® (Brentuximab Vedotin) At The 2019 ASCO Annual Meeting

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced additional analyses of results from ECHELON-1 and ECHELON-2, the frontline phase 3 trials of ADCETRIS ® (brentuximab vedotin), at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting...

Astellas And Seattle Genetics Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate Of 44 Percent In Patients With Most Common Type Of Advanced Urothelial (Bladder) Cancer

Astellas And Seattle Genetics Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate Of 44 Percent In Patients With Most Common Type Of Advanced Urothelial (Bladder) Cancer

-First Investigational Therapy in a Pivotal Trial to Address Unmet Need for Patients with Advanced Urothelial Cancer After Treatment with Platinum Chemotherapy and a PD-1 or PD-L1 Inhibitor-

Robin G. Taylor, M.B.A., Ph.D., Chief Commercial Officer At Seattle Genetics (Photo: Business Wire)

Robin G. Taylor, M.B.A., Ph.D., Chief Commercial Officer At Seattle Genetics (Photo: Business Wire)

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced the appointment of Robin G.

Seattle Genetics Announces Presentations Of New Clinical Data From Multiple Studies Of Novel Targeted Therapies At The American Society Of Clinical Oncology (ASCO) Annual Meeting

Seattle Genetics Announces Presentations Of New Clinical Data From Multiple Studies Of Novel Targeted Therapies At The American Society Of Clinical Oncology (ASCO) Annual Meeting

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced data from six of its proprietary programs will be presented at the upcoming American Society of Clinical Oncology (ASCO) 2019 Annual Meeting taking place May 31 to June 4, 2019 in Chicago.

Seattle Genetics To Present At RBC Capital Markets 2019 Global Healthcare Conference

Seattle Genetics To Present At RBC Capital Markets 2019 Global Healthcare Conference

Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will present at the RBC Capital Markets 2019 Global Healthcare Conference on Wednesday, May 22, 2019 at 8:30 a.

Seattle Genetics Announces Progress In Expanding ADCETRIS® (Brentuximab Vedotin) Indications In Canada

Seattle Genetics Announces Progress In Expanding ADCETRIS® (Brentuximab Vedotin) Indications In Canada

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that Health Canada has approved the supplemental New Drug Submission that expands the use of ADCETRIS (brentuximab vedotin) in combination with AVD (Adriamycin, vinblastine and dacarbazine) chemotherapy...

Seattle Genetics Reports First Quarter 2019 Financial Results

Seattle Genetics Reports First Quarter 2019 Financial Results

Seattle Genetics, Inc. (Nasdaq:SGEN) today reported financial results for the first quarter ended March 31, 2019.

Seattle Genetics To Host Conference Call And Webcast Discussion Of First Quarter 2019 Financial Results On April 25, 2019

Seattle Genetics To Host Conference Call And Webcast Discussion Of First Quarter 2019 Financial Results On April 25, 2019

Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its first quarter 2019 financial results on Thursday, April 25, 2019 after the close of financial markets.

Seattle Genetics Completes Enrollment In Phase 2 Clinical Trial Of Tisotumab Vedotin In Recurrent Or Metastatic Cervical Cancer

Seattle Genetics Completes Enrollment In Phase 2 Clinical Trial Of Tisotumab Vedotin In Recurrent Or Metastatic Cervical Cancer

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced completion of enrollment in the potentially pivotal innovaTV 204 phase 2 clinical trial evaluating the efficacy, safety and tolerability of tisotumab vedotin as monotherapy for patients with recurrent...

Seattle Genetics To Host Conference Call On Positive Topline Results From Pivotal Trial Of Enfortumab Vedotin

Seattle Genetics To Host Conference Call On Positive Topline Results From Pivotal Trial Of Enfortumab Vedotin

Seattle Genetics, Inc. (Nasdaq:SGEN) will host a conference call and webcast discussion regarding the positive topline results from its pivotal clinical trial of enfortumab vedotin in locally advanced or metastatic urothelial cancer, which were announced...

Seattle Genetics Highlights Antibody-Drug Conjugate Innovation And Immuno-Oncology Program At The American Association For Cancer Research (AACR) Annual Meeting

Seattle Genetics Highlights Antibody-Drug Conjugate Innovation And Immuno-Oncology Program At The American Association For Cancer Research (AACR) Annual Meeting

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced data highlights from six presentations showcasing technology advances in the company's antibody-drug conjugate (ADC) platform and an immuno-oncology program at the American Association for Cancer...

Seattle Genetics To Present At Cowen And Company 39th Annual Health Care Conference

Seattle Genetics To Present At Cowen And Company 39th Annual Health Care Conference

Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will present at the Cowen and Company 39 th Annual Health Care Conference on Tuesday, March 12, 2019 at 10:40 a.

Seattle Genetics Achieves $30 Million Milestone Payment For European Commission Approval Of ADCETRIS® (Brentuximab Vedotin) In Frontline Hodgkin Lymphoma

Seattle Genetics Achieves $30 Million Milestone Payment For European Commission Approval Of ADCETRIS® (Brentuximab Vedotin) In Frontline Hodgkin Lymphoma

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that its collaborator, Takeda Pharmaceutical Company Limited, received approval from the European Commission to extend the marketing authorization for ADCETRIS (brentuximab vedotin) to include ADCETRIS...

Seattle Genetics Reports Fourth Quarter And Full Year 2018 Financial Results

Seattle Genetics Reports Fourth Quarter And Full Year 2018 Financial Results

Seattle Genetics, Inc. (Nasdaq:SGEN) today reported financial results for the fourth quarter and year ended December 31, 2018.

TheStreet Quant Rating: C- (Hold)